Dapagliflozin
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Heart Failure, Reduced Ejection Fraction
Conditions
Heart Failure, Reduced Ejection Fraction
Trial Timeline
Apr 19, 2022 → Apr 15, 2024
NCT ID
NCT05250011About Dapagliflozin
Dapagliflozin is a pre-clinical stage product being developed by AstraZeneca for Heart Failure, Reduced Ejection Fraction. The current trial status is completed. This product is registered under clinical trial identifier NCT05250011. Target conditions include Heart Failure, Reduced Ejection Fraction.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06610526 | Approved | Active |
| NCT05250011 | Pre-clinical | Completed |
| NCT03877237 | Phase 3 | Completed |
| NCT03877224 | Phase 3 | Completed |
| NCT03782259 | Approved | Completed |
| NCT03338855 | Approved | Completed |
| NCT03152084 | Approved | Terminated |
| NCT02585804 | Approved | Completed |
| NCT02460978 | Phase 3 | Completed |
| NCT02420392 | Pre-clinical | Completed |
| NCT01294436 | Phase 3 | Completed |
| NCT01165268 | Phase 1 | Completed |
| NCT01055652 | Phase 1 | Completed |
| NCT00908271 | Phase 1 | Completed |
| NCT00726505 | Phase 1 | Terminated |
| NCT00554450 | Phase 1 | Completed |
Competing Products
20 competing products in Heart Failure, Reduced Ejection Fraction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| IV Loop Diuretics | Nuwellis | Pre-clinical | 15 |
| Stepped pharmacologic care | Nuwellis | Phase 3 | 69 |
| IV Loop Diuretics (LD) | Nuwellis | Pre-clinical | 15 |
| TRV120027 + Normal Saline | Trevena | Phase 1 | 25 |
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| TRV120027 + Placebo | Trevena | Phase 1/2 | 33 |
| Ilofotase alfa + Placebo | AM-Pharma | Phase 2 | 44 |
| INXN-4001 | Precigen | Phase 1 | 28 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| SGLT2i, beta blocker, ARNI, MRA, MTD | Eli Lilly | Approved | 85 |
| Pactimibe, CS-505 | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 85 |
| olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil | Daiichi Sankyo | Phase 3 | 77 |
| Olmesartan | Daiichi Sankyo | Phase 3 | 77 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| Advagraf + Prograf | Astellas Pharma | Phase 2 | 52 |
| FK506E | Astellas Pharma | Phase 3 | 77 |